ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Maren Kühr contributed 213 entries already.
Bioxodes SA,based in Marche-en-Famenne, Belgium, has appointed Marc Dechamps as its new CEO. Company founder, Edmond Godfroid, will take up the post of Chief Operations Officer (COO) alongside his existing responsibilities as Chief Scientific Officer (CSO).
French MaaT Pharma has appointed Nathalie Corvaïa as Chief Scientific Officer and will strengthens its R&D Activities in Immuno-Oncology.
Healthcare has long been considered one of the most reliable defensive sectors – an effective portfolio buffer when equity markets turn volatile. That’s because hospitals, drug makers, medical device firms and other companies across the healthcare sector benefit from steady consumer demand – still true?
Fossil carbon is in nearly everything we use in our daily lives ranging from power and fuels to fibers, coatings, and materials used in our clothes, packaging, toys, and household goods. Virgin fossil carbon use in these products is not sustainable given the current understanding of the impact of extracted, emitted, and waste carbon on our environment, climate, and vulnerable populations.
Leiden-based Mimetas, specialist in organ-on-chip-based disease models for drug discovery and development, has appointed Dhaval Patel (UCB, Belgium) as Chair of its Board of Directors.
Oslo-based Lytix Biopharma has a new Chief Business Officer. Stephen Worsley has started at the Norwegian immune-oncology company at the beginning of September.
Finance Expert Pascal Bricout strengthens French Carbios as Chief of Strategy; Financial Officer and a member of the Executive Committee.
Schwan follows Franz, Schinecker follows Schwan.
Beckman Coulter Life Sciences announces that Suzanne Foster has been appointed as president of the company. She succeeds Greg Milosevich, who has left the company.
Jan Van den Bossche becomes the 20th partner of Andera Partners. He joined the Life Sciences team at the beginning of July to accelerate the deployment of its BioDiscovery 6 fund.